Book description
This timely guide to kinase inhibitor drug development is the first to
cover the entire drug pipeline, from target identification to compound
development and clinical application. Edited by the pioneers in the
field, on the drug development side this ready reference discusses
classical medicinal chemistry approaches as well as current chemical
genomics strategies. On the clinical side, both current and future
therapeutic application areas for kinase inhibitor drugs are addressed,
with a strong focus on oncology drugs.
Backed by recent clinical experience with first-generation drugs in the
battle against various forms of cancer, this is crucial reading for
medicinal, pharmaceutical and biochemists, molecular biologists, and
oncologists, as well as those working in the pharmaceutical industry.
Bert Klebl is an expert in small molecule based drug discovery.
Currently, he is managing director and CSO of Lead Discovery Center
GmbH, which was started by Max-Planck Innovation and the Max-Planck
Society. Before, he was at GPC Biotech, Axxima Pharmaceuticals and
Aventis (Hoechst Marion Roussel). A biochemist by training, he graduated
from the University of Konstanz, Germany, and did post-doctoral work at
the Biotechnology Research Institute in Montreal, Canada.
Gerhard Muller received his PhD in Organic Chemistry in 1992 from the
Technical University of Munich, working with Horst Kessler. After two
years in the Medicinal Chemistry Department of Glaxo Verona (Italy), he
joined the Central Research Facility of Bayer AG in Leverkusen. From
2001 to 2003 he headed the chemistry department of Organon's Lead
Discovery Unit is Oss, Netherlands. In 2003 he was nominated CSO of
Axxima Pharmaceuticals AG in Munich, and upon its acquisition through
GPC Biotech AG in 2005, he became GPC's Vice President Drug Discovery.
Since 2008 he is CSO and Managing Director of Proteros Fragments GmbH,
specializing in fragment-based lead generation. Apart from numerous
scientific articles and patents, he co-edited the "Chemogenomics in
Drug Discovery" book of this series on medicinal chemistry.
Michael Hamacher studied biology at the Heinrich-Heine-Universitat in
Dusseldorf, Germany. Subsequent to his PhD, he joined the Medizinisches
Proteom-Center, Ruhr-Universitat Bochum, Germany, and became Head of
Administration of the MPC, responsible for the implementation and the
strategical planning of the Human Brain Proteome Project under the roof
of the Human Proteome Organisation (HUPO BPP) among others. In 2008, he
moved to the Lead Discovery Center GmbH, Dortmund, Germany, for the same
position, focussing on preparing national as well as international
funding applications, on project management, budgeting as well as human
resources. He applied and implemented numerous projects in early
pharmaceutical research.
